Compare Stocks: CLDX, HALO, ARWR, and SMMT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$86.49 +1.3%	$83.96	$27.10 ▼ $95.49	$12.02B	1.28	1.09 million shs	1.37 million shs
CLDX Celldex Therapeutics	$39.37 -0.3%	$38.98	$22.10 ▼ $45.14	$3.10B	0.84	758,933 shs	416,697 shs
HALO Halozyme Therapeutics	$110.76 +1.0%	$90.05	$61.22 ▼ $111.15	$12.45B	0.88	2.36 million shs	1.89 million shs
SMMT Summit Therapeutics	$17.13 +17.3%	$14.17	$12.07 ▼ $29.23	$11.65B	-1.24	5.58 million shs	14.88 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.18%	-4.21%	-0.74%	+13.58%	+232.44%
CLDX Celldex Therapeutics	+0.61%	-2.69%	+4.75%	+31.91%	+78.97%
HALO Halozyme Therapeutics	+1.80%	+2.43%	+33.29%	+53.16%	+49.52%
SMMT Summit Therapeutics	+3.11%	+2.60%	+11.88%	-1.62%	-38.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$86.49 +1.3%	$83.96	$27.10 ▼ $95.49	$12.02B	1.28	1.09 million shs	1.37 million shs
CLDX Celldex Therapeutics	$39.37 -0.3%	$38.98	$22.10 ▼ $45.14	$3.10B	0.84	758,933 shs	416,697 shs
HALO Halozyme Therapeutics	$110.76 +1.0%	$90.05	$61.22 ▼ $111.15	$12.45B	0.88	2.36 million shs	1.89 million shs
SMMT Summit Therapeutics	$17.13 +17.3%	$14.17	$12.07 ▼ $29.23	$11.65B	-1.24	5.58 million shs	14.88 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	+3.18%	-4.21%	-0.74%	+13.58%	+232.44%
CLDX Celldex Therapeutics	+0.61%	-2.69%	+4.75%	+31.91%	+78.97%
HALO Halozyme Therapeutics	+1.80%	+2.43%	+33.29%	+53.16%	+49.52%
SMMT Summit Therapeutics	+3.11%	+2.60%	+11.88%	-1.62%	-38.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.62	Moderate Buy	$98.42	13.79% Upside
CLDX Celldex Therapeutics	2.85	Moderate Buy	$56.08	42.45% Upside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-17.66% Downside
SMMT Summit Therapeutics	2.44	Hold	$24.07	40.53% Upside

Current Analyst Ratings Breakdown

Latest CLDX, HALO, ARWR, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/2/2026	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
9/1/2026	SMMT Summit Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$120.00
8/31/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/31/2026	ARWR Arrowhead Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$100.00
8/31/2026	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$115.00
8/26/2026	SMMT Summit Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/25/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$11.90
8/25/2026	SMMT Summit Therapeutics	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform	$9.80 ➝ $11.90

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$669.50M	18.20	$0.12 per share	692.96	$3.31 per share	26.13
CLDX Celldex Therapeutics	$1.54M	2,007.61	N/A	N/A	$9.10 per share	4.33
HALO Halozyme Therapeutics	$1.40B	9.00	$4.91 per share	22.58	$1.26 per share	87.90
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.79 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$1.63M	-$2.25	N/A	N/A	N/A	-47.79%	-60.06%	-17.37%	N/A
CLDX Celldex Therapeutics	-$258.76M	-$4.35	N/A	N/A	N/A	N/A	-52.35%	-47.61%	11/9/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	33.06	11.99	0.43	24.86%	260.98%	23.91%	11/2/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest CLDX, HALO, ARWR, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CLDX Celldex Therapeutics	-$1.06	-$0.94	+$0.12	-$0.94	$0.74 million	$0.02 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/4/2026	Q3 2026	ARWR Arrowhead Pharmaceuticals	-$1.23	-$1.36	-$0.13	-$1.36	$44.17 million	$75.25 million
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CLDX Celldex Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	1.77	5.90	5.90
CLDX Celldex Therapeutics	N/A	11.82	11.82
HALO Halozyme Therapeutics	13.50	2.71	2.31
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
CLDX Celldex Therapeutics	N/A
HALO Halozyme Therapeutics	97.79%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	3.60%
CLDX Celldex Therapeutics	5.20%
HALO Halozyme Therapeutics	2.50%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	140.86 million	135.79 million	Optionable
CLDX Celldex Therapeutics	150	78.53 million	74.45 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable
SMMT Summit Therapeutics	110	797.75 million	131.63 million	Optionable

CLDX, HALO, ARWR, and SMMT Headlines

Recent News About These Companies

Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.

10 minutes ago | seekingalpha.com

Summit packs a punch for Merck's Keytruda — but not everyone is sold

September 3 at 6:11 PM | msn.com

Summit Therapeutics Stock Rises 11%

September 3 at 1:01 PM | rttnews.com

Better cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer study

September 3 at 1:01 PM | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - What's Next?

September 3 at 11:59 AM | marketbeat.com

November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet

September 3 at 7:00 AM | seekingalpha.com

Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China

September 2 at 7:00 PM | businesswire.com

Ten healthcare stocks leading in year-over-year CapEx growth

September 2 at 8:33 AM | msn.com

Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Rating of "Hold" by Brokerages

September 2 at 1:59 AM | americanbankingnews.com

Summit Therapeutics (NASDAQ:SMMT) Trading 4.9% Higher - Here's What Happened

September 1 at 3:00 PM | marketbeat.com

The Manufacturers Life Insurance Company Invests $4.34 Million in Summit Therapeutics PLC $SMMT

September 1 at 4:48 AM | marketbeat.com

Hsbc Holdings PLC Invests $1.78 Million in Summit Therapeutics PLC $SMMT

August 31 at 5:04 AM | marketbeat.com

Beacon Pointe Advisors LLC Purchases Shares of 98,114 Summit Therapeutics PLC $SMMT

August 31 at 3:28 AM | marketbeat.com

Summit Therapeutics Inc.

August 30, 2026 | barrons.com

BlackRock Inc. Invests $138.84 Million in Summit Therapeutics PLC $SMMT

August 29, 2026 | marketbeat.com

Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Recommendation of "Hold" from Analysts

August 28, 2026 | marketbeat.com

HC Wainwright Reiterates Neutral Rating for Summit Therapeutics (NASDAQ:SMMT)

August 28, 2026 | americanbankingnews.com

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

August 27, 2026 | zacks.com

Ivonescimab beats Imfinzi in Chinese biliary tract cancer trial

August 27, 2026 | thepharmaletter.comT

Deutsche Bank AG Makes New $3.49 Million Investment in Summit Therapeutics PLC $SMMT

August 27, 2026 | marketbeat.com

Summit Therapeutics (SMMT) Published Phase III HARMONi Results In The Lancet Oncology

August 27, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CLDX, HALO, ARWR, and SMMT Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$86.49 +1.12 (+1.31%)

As of 04:00 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Celldex Therapeutics NASDAQ:CLDX

$39.37 -0.11 (-0.28%)

As of 04:00 PM Eastern

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Halozyme Therapeutics NASDAQ:HALO

$110.76 +1.10 (+1.00%)

As of 04:00 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Summit Therapeutics NASDAQ:SMMT

$17.13 +2.53 (+17.33%)

As of 04:00 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, HALO, ARWR, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, HALO, ARWR, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, HALO, ARWR, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLDX, HALO, ARWR, and SMMT Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Celldex Therapeutics NASDAQ:CLDX

Halozyme Therapeutics NASDAQ:HALO

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CLDX, HALO, ARWR, and SMMT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CLDX, HALO, ARWR, and SMMT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CLDX, HALO, ARWR, and SMMT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CLDX, HALO, ARWR, and SMMT Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

Celldex Therapeutics NASDAQ:CLDX

Halozyme Therapeutics NASDAQ:HALO

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools